in the surgery and lymph node involvement. The Statistical analysis was performed with SPSS for Mac version 20.0. A description of the main variables included was made. In addition, we ran a multivariate analysis through linear regression, using the Enter method, with the objective of analyze the prognostic factors associated with the presence of uterine sarcoma. The calculation of the magnitude of association was made using the OR and its corresponding confidence interval at the 95% (95% CI). In all hypothesis tests, a significance level of 0.05 was considered.

Result(s)* The incidence of uterine sarcoma in our setting was 5.35% (total uterine cancer: 859). The mean age was (53.5 ± 10.9) and the BMI (29.9 ± 9.1) . There were 30 leiomyosarcomas (63.8%), 16 endometrial stromal sarcomas (34%) and a high-grade adenocarcinoma (2.1%). If we look at the staging, IA (14 (29.8%)); IB (13 (27.7%)); IIA (1 (2.1%)); IIB (3 (6.4%)), there was no case of IIIA; IIIB (2 (4.3%)); IIIC (2 (4.3%)); IV A (2 (4.3%)) and IV B (10 (21.3%)). In multivariate analysis using logistic regression, leaving free margins in the piece, acts as a protective factor (OR -2.13; CI 95% 0.02-0.6 (p value 0.01)). Having lymph node involvement does not behave as a prognostic factor in this study and the morcellation and/or fragmentation variable was eliminated from the study after a fitted model.

Conclusion* For tumors limited to uterus, the prognostic factors described are: tumor size, mitotic index, tumor necrosis, vascular invasion, free surgical margins and morcellation. In our sample and according to what has been published, we can conclude that the surgery will determine the prognosis. Being fundamental keep margins free on the piece to improve prognosis.

563

PATIENT SATISFACTION SURVEY: INTRODUCTION OF A TELEMEDICINE OUTPATIENT REVIEW SERVICE IN A GYNAECOLOGY-ONCOLOGY CENTRE DURING COVID-19

¹S Addley, ²N Sadeghi, ²H Soleymani Majd*. ¹University Hospitals of Derby and Burton NHS Foundation Trust, Gynaecology Oncology, UK; ²Oxford University Hospitals NHS Foundation Trust, Gynaecology Oncology, UK

10.1136/ijgc-2021-ESGO.271

Introduction/Background* With the outbreak of the COVID-19, the National Health Service has had to rapidly adapt many systems. One such change to the delivery of patient care has been the increasing use of TeleMedicine during the pandemic.

Methodology A new TeleMedicine outpatient review service was introduced in a Gynaecology-Oncology centre in April 2020 in response to COVID-19. To determine patient satisfaction with this change in practice, a dedicated feedback questionnaire was devised. All patients who received a TeleMedicine consultation from one Consultant-led Gynaecology-Oncology clinic in November 2020 were offered the opportunity to participate in the voluntary and anonymous survey

Result(s)* Response rate was 100% (n=19). All patients confirmed feeling 'safer' receiving a telephone review. All found TeleMedicine 'highly convenient'; and for 18 (95%) it was

'less costly'. 11 (58%) calls were made on time. 3 patients (16%) missed the initial call. Patients confirmed that the clinician introduced themselves in 18 (95%) cases; explaining the purpose of the call 89% of the time. 2 patients (11%) experienced technical problems with reception and volume. 84% expressed 'no concern' discussing health issues via phone; and 95% interpreted the clinician's communication as 'clear'. All felt 'listened to' and 16 (84%) had been given the opportunity for questions. 16 (84%) were 'content' with omission of physical examination. 17 (89%) were advised how to seek help if needed. The majority (79%) were 'very satisfied' with the service. 2 (11%) would decline further TeleMedicine review.

Conclusion* Gynaecology-Oncology patients appear overall satisfied with replacement of face-to-face outpatient consultations with TeleMedicine during the ongoing pandemic. To ensure quality of care and patient safety – patient triaging; TeleMedicine proformas; use of video; and low threshold for escalation – are all important considerations.

575

RECTUS SHEATH CATHETERS VERSUS EPIDURAL ANALGESIA FOR OPEN MIDLINE INCISIONS IN MAJOR GYNAECOLOGICAL- ONCOLOGY SURGERY

D Kaludova*, A Rechner, F Correia Martins, P Pathiraja. Addenbrooke's Hospital, UK

10.1136/ijgc-2021-ESGO.272

Introduction/Background* Rectus sheath catheters (RSCs) have frequently been used in several surgical specialities. The aim of the project was to compare the efficacy of RSCs and epidural analgesia (EA) in the post op period in patients who underwent major Gynae-Oncology surgery requiring midline incisions in terms of time to discharge, time to removal of urinary catheter (TWOC), patient experience.

Methodology We retrospectively analyzed two main groups of patients- patients who had RSCs and patients who had EA as a primary mode of post-operative analgesia (PMPOA). We used ChiSquare and Students T.test to compare the group variables for statistical significance.

Result(s)* A total of 39 patients were identified- 20 with RSCs and 19 with EA. The two groups of patients were commenced on post-op PCA in addition to the PMOPA. All patients with RSCs had PCA. 8 out of 19 patients with EA did not have PCA. Within each group patients were on variable PCA types with the most used Fentanyl and Morphine. There was no significant difference on types of PCA used (p=0.054) and ASA (p=0.341). Perception of postoperative pain was not significantly different between RSC and EA groups. In the RSC group there was a significantly shorter post-operative time between surgery and TWOC (p=0.0036) and between surgery and discharge when compared with the EA group (p=0.0051).

Conclusion* Our data shows that patients who had RSCs were ready for discharge sooner than the patients who had EA. RSCs may have a place as a PMPOA in Gynae-Oncology patients requiring full-length midline incisions. Furthermore, if RSCs are implemented as a standard practice for PMPOA it may have a health-economic benefit.